New drug cocktail shows promise for rare blood cancer
NCT ID NCT03623373
First seen Apr 02, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tested a combination of targeted therapy (acalabrutinib) and chemotherapy in 13 people with untreated mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach could safely shrink tumors enough to allow a stem cell transplant. The treatment was given in two phases, and researchers measured how well stem cells could be collected afterward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.